Business Description
Acer Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US00444P1084
Description
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.05 | |||||
| Equity-to-Asset | -2.27 | |||||
| Debt-to-Equity | -0.97 | |||||
| Debt-to-EBITDA | -1.64 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 19.2 | |||||
| 3-Year EPS without NRI Growth Rate | 16.9 | |||||
| 3-Year FCF Growth Rate | 13.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 11.91 | |||||
| 9-Day RSI | 22.33 | |||||
| 14-Day RSI | 30.17 | |||||
| 6-1 Month Momentum % | -0.35 | |||||
| 12-1 Month Momentum % | -29.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.16 | |||||
| Quick Ratio | 0.05 | |||||
| Cash Ratio | 0.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -24.8 | |||||
| Shareholder Yield % | -62.98 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -240.73 | |||||
| ROIC % | -72.03 | |||||
| ROC (Joel Greenblatt) % | -14853.6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 5.5 | |||||
| EV-to-EBIT | -2.37 | |||||
| EV-to-EBITDA | -2.37 | |||||
| EV-to-Forward-EBITDA | -1.18 | |||||
| EV-to-Forward-Revenue | 0.97 | |||||
| EV-to-FCF | -1.46 | |||||
| Earnings Yield (Greenblatt) % | -42.19 | |||||
| FCF Yield % | -198.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ACER
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Acer Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.95 | ||
| Beta | 0 | ||
| Volatility % | 137.6 | ||
| 14-Day RSI | 30.17 | ||
| 14-Day ATR ($) | 0.076348 | ||
| 20-Day SMA ($) | 0.830315 | ||
| 12-1 Month Momentum % | -29.91 | ||
| 52-Week Range ($) | 0.5515 - 4.56 | ||
| Shares Outstanding (Mil) | 24.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Acer Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Acer Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Acer Therapeutics Inc Frequently Asked Questions
What is Acer Therapeutics Inc(ACER)'s stock price today?
The current price of ACER is $0.66. The 52 week high of ACER is $4.56 and 52 week low is $0.55.
When is next earnings date of Acer Therapeutics Inc(ACER)?
The next earnings date of Acer Therapeutics Inc(ACER) is 2024-05-16 Est..
Does Acer Therapeutics Inc(ACER) pay dividends? If so, how much?
Acer Therapeutics Inc(ACER) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers